Earnings Call Summary | KIMBERLY-CLARK DE MEXICO SAB DE CV ADR-REPR 5 ORD'A'NPV(KCDMY.US) Q2 2024 Earnings Conference
Earnings Call Summary | KIMBERLY-CLARK DE MEXICO SAB DE CV ADR-REPR 5 ORD'A'NPV(KCDMY.US) Q2 2024 Earnings Conference
The following is a summary of the Kimberly-Clark De México, S. A. B. De C. V. (KCDMY) Q2 2024 Earnings Call Transcript:
以下是金佰利墨西哥公司(KCDMY)2024年第二季度業績會成績摘要:
Financial Performance:
金融業績:
Kimberly-Clark de Mexico reported record Q2 net sales of MXN 14.1 billion, a 2.6% increase year-over-year.
EBITDA grew to MXN 4 billion, a 14.8% increase, with a margin improvement to 28.7%.
Net income rose to MXN 2.1 billion, an 18.5% increase, with earnings per share at MXN 0.69.
Cost of goods sold decreased by 4%, with cost reduction programs yielding about MXN 400 million in savings.
金佰利墨西哥報告了創紀錄的第二季度淨銷售額爲141億墨西哥披索,同比增長2.6%。
EBITDA增長到40億墨西哥披索,同比增長14.8%,淨利率提高至28.7%。
淨收益增至21億墨西哥披索,同比增長18.5%,每股收益爲0.69墨西哥披索。
銷售成本減少4%,成本降低計劃節省約4千萬墨西哥披索。
Business Progress:
業務進展:
Continued strong performance in the Consumer Products segment and significant growth in exports of finished products by 67.7%.
Innovations launched in key product categories like Huggies Diapers and Kotex Fenpatch.
Investments in manufacturing to enhance flexibility in using cost-effective materials.
消費產品板塊繼續表現強勁,成品出口增長了67.7%。
在Huggies尿褲和Kotex Fenpatch等關鍵產品類別推出的創新產品上市。
加強制造業投資,提高使用成本效益材料的靈活性。
Opportunities:
機會:
Expectation of continued strong sales driven by innovations and commercial execution.
Positive trends expected in tissue parent rolls and exports due to optimizing the North American supply chain.
預計創新和商業運營的持續強勁銷售。
由於優化北美供應鏈,預計組織母卷和出口的積極趨勢。
Risks:
風險:
Impact of rising pulp costs and exchange rate fluctuations on financial results.
Persistent competition and price sensitivity in the market could affect volume and margin performance.
漿紙成本上漲和匯率波動對財務成果的影響。
市場上持續的競爭和價格敏感性可能會影響銷量和利潤表現。
More details: KIMBERLY-CLARK DE MEXICO SAB DE CV ADR-REPR 5 ORD'A'NPV IR
更多細節:金佰利墨西哥公司有限公司ADRR-REPR 5 ORD 'A' NPV IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。